1-3 of 3
Thomas Mueller
Close
Sort by
Journal Articles

Does the haplotype Met408-Del420, which was apparently predictive for imatinib efficacy, really exist and how strongly may it affect OCT1 activity?

Mladen V. Tzvetkov, Tina Seitz, Kristin Bokelmann, Thomas Mueller, Jürgen Brockmöller, Hermann Koepsell
Journal: Blood
Blood (2014) 123 (9): 1427–1429.
https://doi.org/10.1182/blood-2013-11-535864
Published: 2014
Journal Articles

Evidence for an Underestimation of the Prognostic Impact of Poor Cytogenetics within the IPSS.

Detlef Haase, MD, PhD, Ulrich Germing, MD, PhD, Julie Schanz, MD, Michael Pfeilstoecker, MD, PhD, Barbara Hildebrandt, PhD, Michael Luebbert, MD, PhD, Aristoteles Giagounidis, MD, Carlo Aul, MD, PhD, Lorenz Truemper, MD, PhD, Thomas Mueller, PhD, Peter Valent, MD, PhD, Norbert Gattermann, MD, PhD, Christa Fonatsch, PhD, Otto Krieger, MD, PhD, Reinhard Stauder, MD, Christian Steidl, MD
Journal: Blood
Blood (2006) 108 (11): 252.
https://doi.org/10.1182/blood.V108.11.252.252
Published: 2006
Journal Articles

New and Comprehensive Cytogenetic Prognostication and Categorization in MDS.

Detlef Haase, MD, PhD, Ulrich Germing, MD, PhD, Julie Schanz, MD, Michael Pfeilstoecker, MD, PhD, Thomas Noesslinger, MD, Barbara Hildebrandt, PhD, Andrea Kuendgen, MD, Michael Luebbert, MD, PhD, Aristoteles Giagounidis, MD, Carlo Aul, MD, PhD, Lorenz Truemper, MD, PhD, Thomas Mueller, PhD, Peter Valent, MD PhD, Christa Fonatsch, MD, PhD, Christian Steidl, MD
Journal: Blood
Blood (2006) 108 (11): 248.
https://doi.org/10.1182/blood.V108.11.248.248
Published: 2006